# A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

> **NCT04578847** · PHASE2 · UNKNOWN · sponsor: **National Research Center for Hematology, Russia** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia in Remission
- BCR-ABL Positive Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Nilotinib
- **DRUG:** Dasatinib
- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT04578847
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578847, "A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04578847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*